Results 211 to 220 of about 101,476 (335)

Cutaneous lymphomas

open access: bronze, 1984
Mark Allen Everett
openalex   +1 more source

Cutaneous epitheliotropic lymphoma in a ferret [PDF]

open access: bronze, 1996
Michele Rosenbaum   +3 more
openalex   +1 more source

Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Methotrexate (MTX) has been a longstanding therapeutic option for mycosis fungoides (MF); however, data on its real‐world effectiveness remain limited. This study aimed to assess real‐world outcomes of oral MTX in the treatment of MF. Data from five referral centres for cutaneous lymphoma in Greece were retrospectively reviewed with the baseline‐ and ...
Vasiliki Nikolaou   +21 more
wiley   +1 more source

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. [PDF]

open access: yesBr J Dermatol, 2021
Quaglino P   +66 more
europepmc   +1 more source

Acneiform type of mogamulizumab‐associated rash

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Inga Hansen‐Abeck   +5 more
wiley   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg   +31 more
wiley   +1 more source

Erythema annulare centrifugum and Hodgkin lymphoma during pregnancy

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Valentine Horiot   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy